


PHARMACEUTICAL 2017

Theriva Biologics Inc. Rank 241 of 292





PHARMACEUTICAL 2017

Theriva Biologics Inc. Rank 241 of 292

The relative strengths and weaknesses of Theriva Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theriva Biologics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Theriva Biologics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is -112%, being 115% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	21,570
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,757
Liabilities, Non-Current	0
Other Assets	23
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	492
Other Net Income	11,449
Other Revenues	0
Property and Equipment	905
Research and Development	29,109
Selling, General and Administrative Expense	10,143

Output Variable	Value in 1000 USD
Assets	22,498
Liabilities	20,249
Expenses	39,252
Revenues	0
Stockholders Equity	2,249
Net Income	-27,803
Comprehensive Net Income	-27,803
Economic Capital Ratio	-112%

